← Eichor
Study identifier: NCT03820492 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Comparison of Optical Coherence Tomography-derived Minimal Lumen Area, Invasive Fractional Flow Reserve and FFRCT

Condition: Coronary Stenosis  ·  Sponsor: Insel Gruppe AG, University Hospital Bern

PhaseNA
Planned participants104
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Significant left main (LM) stenosis is associated with a poor prognosis, therefore, adequate judgement of the prognostic significance of LM stenosis is essential to improve patients' prognosis. Recently, fractional flow reserve (FFR) has become widespread practice and carries a Class Ia recommendation to assess functional significance of intermediate coronary stenosis in patients with stable angina. Intravascular ultrasound (IVUS)-derived minimum lumen area (MLA) represents an accurate measure to determine LM significance as shown in multiple studies, while optical coherence tomography (OCT) ,which is a novel intracoronary imaging method with a greater spatial resolution (15μm vs. 100μm), faster image acquisition and facilitated image interpretation, OCT derived-MLA has never been validated against FFR and accordingly, it is not mentioned in the current guidelines for myocardial revascularization. Coronary computed tomography angiography (CTA) has emerged as a noninvasive alternative of coronary angiography with its excellent negative predictive value, while the positive predictive value of CTA is limited. Computational fluid dynamics is an emerging method that enables prediction of blood flow in coronary arteries and calculation of FFR from computed tomography (FFRCT) noninvasively. Noninvasive and accurate assessment of functional significance would bring a great benefit for patients with LM stenosis, however, there are no data to evaluate the diagnostic accuracy of FFRCT f…

This description comes directly from the study's public registry record.

Talk to the study team

Lorenz Raeber, Prof. MD PhD  ·  +41316322111  ·  lorenz.raeber@insel.ch

Hiroki Shinutani, MD  ·  +41316322111  ·  hiroki.shibutani@extern.insel.ch

Always discuss trial participation with your own doctor first.

Locations (13)

Centre Hospitalier Universitaire de Clermont-FerrandClermont-Ferrand, FranceRecruiting
Institute Mutualiste MontsourisParis, FranceRecruiting
Centre Cardiologique du NordSaint-Denis, FranceRecruiting
Universitätsklinikum Giessen Justus-Liebig UniversitätGiessen, Hesse, GermanyRecruiting
Friedrich Alexander Universität (FAU) , Medizinische Klinik 2 , Kardiologie und AngiologieErlangen, GermanyRecruiting
Ageo Central General HospitalAgeo, JapanRecruiting
Gifu heart centerGifu, JapanRecruiting
Department of Cardiovascular Medicine Shinshu University School of MedicineNagano, JapanRecruiting
Kansai Medical University,Osaka, JapanRecruiting
Medical Corporation Ouyuukai Tokorozawa Heart CenterSaitama, JapanRecruiting
Sapporo Higashi Tokushukai HospitalSapporo, JapanRecruiting
InselspitalBern, SwitzerlandRecruiting

+ 1 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT03820492